Pediatrix Medical Group (MD) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for May 8, 2025, to be held virtually for shareholders of record as of March 10, 2025.
Shareholders are encouraged to review proxy materials online and may request paper or email copies by April 28, 2025.
Voting matters and shareholder proposals
Election of eight directors for terms expiring at the next annual meeting or until successors are elected and qualified.
Ratification of PricewaterhouseCoopers LLP as independent auditor for the 2025 fiscal year.
Advisory vote on executive compensation for the 2024 fiscal year.
Consideration of other business as may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting FOR all three main proposals, including director elections and auditor ratification.
Eight nominees listed for director election, including Laura A. Linynsky, Thomas A. McEachin, Mark S. Ordan, Michael A. Rucker, Guy P. Sansone, John M. Starcher, Jr., Shirley A. Weis, and Sylvia J. Young.
Latest events from Pediatrix Medical Group
- Q4 2025 delivered strong EBITDA and net income, with 2026 EBITDA growth projected at 5%.MD
Q4 202519 Feb 2026 - Q2 net loss from impairments; restructuring and new leadership target $30M EBITDA boost.MD
Q2 20242 Feb 2026 - Refocusing on core hospital-based care, with stable demand and growth in maternal-fetal medicine.MD
Jefferies Global Healthcare Conference1 Feb 2026 - Q3 revenue up 0.9%, Adjusted EBITDA rises, but impairments drive a nine-month net loss.MD
Q3 202417 Jan 2026 - Q4 2024 showed robust results and a prudent 2025 outlook after portfolio restructuring.MD
Q4 202423 Dec 2025 - Board recommends approval of all proposals, with a focus on performance-based executive pay and governance.MD
Proxy Filing2 Dec 2025 - Q1 net income rose to $20.7M, Adjusted EBITDA hit $49.2M, and guidance was raised.MD
Q1 202525 Nov 2025 - Q2 2025 saw strong EBITDA, raised guidance, and robust cash flow with improved profitability.MD
Q2 202523 Nov 2025 - Q3 net income hit $71.7M, Adjusted EBITDA $87.3M; 2025 guidance raised to $270–$290M.MD
Q3 202513 Nov 2025